A new Wall Street Journal report says there are a few reasons why a company might list a job, but never follow through and hire someone.

Companies are posting robust results so far this earnings season, but the bar is high for stock gains to continue.

Stifel analyst Rick Wise lowered the firm’s price target on Johnson & Johnson to $155 from $170 and keeps a Hold rating on the shares.

We recently compiled a list of the Billionaire Prem Watsa’s Top 15 Long-Term Stock Picks. In this article, we are going to ...

Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee ...

Loss of breadth: Check. A handful of technology giants-what UBS calls the 'Magnificent Six,' which excludes Tesla -are driving the market, while smaller stocks lag. The average 12-month forward ...

Johnson & Johnson (NYSE: JNJ) is an elite dividend stock. The healthcare giant has increased its dividend payment for 62 ...

Wall Street's indexes rose on Wednesday, with the benchmark S&P 500 hitting an intraday record high as investors cheered streaming video provider Netflix's quarterly report and President Donald ...

Johnson & Johnson reported better-than-expected quarterly revenue and profit on higher sales of cancer drugs and some medical devices. But shares slipped 3.2% to $143.35 in Wednesday morning trading, ...

Wall Street indexes hit new highs, driven by optimism in tech stocks, following President Trump's announcement of a $500 ...

J&J’s 2025 results will be the launching point for its guidance of 5%-7% revenue growth for 2025-30, which is still well ...